xpertsystems/hccar001-sample

这是一个双表纵向心力衰竭患者数据集，涵盖了心力衰竭队列的完整临床研究数据表面：基线患者记录（每名患者约114个特征，包括人口统计学、完整超声心动图评估（含舒张功能）、14种生物标志物（包括BNP/NT-proBNP/肌钙蛋白/CKD-EPI eGFR）、指南导向药物治疗（GDMT）四支柱处方、设备治疗（ICD/CRT/LVAD/移植）、住院结局、功能状态（NYHA、6MWD、KCCQ、VO₂ max）、合并症和生命体征）以及为期3年的季度随访访问，跟踪LVEF/BNP/NYHA轨迹。该数据集针对多个临床和监管标准进行了校准，包括ACC/AHA 2022心力衰竭指南、ASE 2016左心室舒张功能评估建议、CKD-EPI 2009、PINNACLE注册表（真实世界GDMT处方率）、CMS HRRP（30天再入院基准）、SCD-HeFT/DINAMIT（一级预防ICD标准）和CARE-HF/COMPANION（CRT资格标准）。样本预览包含200名患者×3年内12次季度访问（200条基线记录+2,400条访问记录，约500 KB）。完整产品覆盖10,000+名患者×完整3年随访，并扩展了超声心动图/CMR模块、完整CPET/设备询问细节、完整药物滴定轨迹，以及预建队列配置，用于HFrEF临床试验模拟、HFpEF治疗效果异质性研究和心肾-心脏代谢合并症分析。This is a two-table longitudinal heart failure patient dataset covering the full spectrum of clinical research data for heart failure cohorts, including baseline patient records and 3-year quarterly follow-up visits. Baseline patient records contain approximately 114 features per patient, covering demographics, comprehensive echocardiographic assessments (including diastolic function evaluation), 14 biomarkers (including BNP/NT-proBNP, troponin, and CKD-EPI eGFR), four-pillar guideline-directed medical therapy (GDMT) prescriptions, device therapies (ICD, CRT, LVAD, and cardiac transplantation), hospitalization outcomes, functional status metrics (NYHA functional classification, 6-minute walk distance [6MWD], Kansas City Cardiomyopathy Questionnaire [KCCQ], and peak VO₂), comorbidities, and vital signs. The 3-year quarterly follow-up visits track the longitudinal trajectories of LVEF, BNP, and NYHA functional class. This dataset has been calibrated against multiple clinical and regulatory standards, including the ACC/AHA 2022 Heart Failure Guidelines, ASE 2016 Recommendations for the Evaluation of Left Ventricular Diastolic Function, CKD-EPI 2009 Equation, PINNACLE Registry (real-world GDMT prescription rates), CMS HRRP (30-day readmission benchmark), SCD-HeFT/DINAMIT (primary prevention ICD eligibility criteria), and CARE-HF/COMPANION (CRT eligibility criteria). The sample preview includes data from 200 patients with 12 quarterly follow-up visits over 3 years, comprising 200 baseline records and 2,400 follow-up records, with a total size of approximately 500 KB. The full product covers over 10,000 patients with complete 3-year follow-up, and additionally features expanded echocardiography/CMR modules, comprehensive cardiopulmonary exercise testing (CPET) and device interrogation details, full medication titration trajectories, and pre-built cohort configurations for HFrEF clinical trial simulation, HFpEF treatment effect heterogeneity research, and cardiorenal-cardiovascular metabolic comorbidity analysis.